Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2018 Jan 18;19(2):142-146.
doi: 10.1002/cbic.201700538. Epub 2017 Dec 7.

A T7 RNA Polymerase Mutant Enhances the Yield of 5'-Thienoguanosine-Initiated RNAs

Affiliations

A T7 RNA Polymerase Mutant Enhances the Yield of 5'-Thienoguanosine-Initiated RNAs

Seth Lyon et al. Chembiochem. .

Abstract

Spectroscopic methods, which are used to establish RNA structure-function relationships, require strategies for post-synthetic, site-specific incorporation of chemical probes into target RNAs. For RNAs larger than 50 nt, the enzymatic incorporation of a nucleoside or nucleotide monophosphate guanosine analogue (G analogue) at their 5'-end is routinely achieved by T7 RNA polymerase (T7RNAP)-mediated in vitro transcription (IVT) of the appropriate DNA template containing a GTP-initiating class III Φ6.5 promoter. However, when high G analogue:GTP ratios are used to bias G analogue incorporation at the 5'-end, RNA yield is compromised. Here, we show that the use of a T7RNAP P266L mutant in IVT with 10:1 thienoguanosine (th G):GTP increased the percent incorporation and yield of 5'-th G-initiated precursor tRNA for a net ≈threefold gain compared to IVT with wild-type T7RNAP. We also demonstrated that a one-pot multienzyme approach, consisting of transcription by T7RNAP P266L and post-transcriptional cleanup by polyphosphatase and an exonuclease, led to essentially near-homogeneous 5'-th G-modified transcripts. This approach should be of broad utility in preparing 5'-modified RNAs.

Keywords: RNA; T7 RNA polymerase; fluorescent probes; in vitro transcription; thienoguanosine.

PubMed Disclaimer

Figures

Figure 1
Figure 1
(A) Structure of guanosine triphosphate and thienoguanosine (thG). (B) Secondary structure of pre-tRNACys, the model RNA used in this study. The sequences of the 5'-leader and 3'-trailer are provided below the secondary structure.
Figure 1
Figure 1
(A) Structure of guanosine triphosphate and thienoguanosine (thG). (B) Secondary structure of pre-tRNACys, the model RNA used in this study. The sequences of the 5'-leader and 3'-trailer are provided below the secondary structure.
Figure 2
Figure 2
(A) Schematic of the expected outcomes during an IVT that has a fixed ratio of thG:GTP and was peformed using either T7RNAP WT or P266L mutant. This illustration depicts qualitatively the gains with respect to abortive transcription (also, see Figure S2). (B) Comparison of a typical IVT versus the one-pot multi-enzyme approach designed to eliminate 5'-GTP-initiated RNAs.
Figure 3
Figure 3
(A) Purity of recombinant T7RNAP used in this study, as demonstrated by SDS-PAGE [10% (w/v) polyacrylamide] analysis. (B) One µl from a 100-µl IVT performed using either T7RNAP WT (lane 1) or P266L (lane 2) was electrophoresed on a 2% (w/v) agarose gel and stained with ethidium bromide; samples examined were from post-DNase I treatment. Lane 3 has 1 µg of the final pre-tRNACys 55–23 RNA that was generated using the OPME (post-IVT RppH and Xrn-1) approach. (C) Fluorescence (λexc, 312 nm) of 5 µM RNA obtained after IVT with T7RNAP WT (1) or P266L (2), or using the OPME method with P266L (3). (D) RNA yields (grey) and % incorporation of thG (purple) with T7RNAP WT (1) or P266L (2), or using the OPME method with P266L (3). Mean and standard deviation values were calculated from three independent measurements.

Similar articles

Cited by

References

    1. Alexander S, Devaraj N, Biochemistry 2017, 56, 5185–5193. - PubMed
    1. Paredes E, Evans M, Das SR, Methods 2011, 54, 251–259. - PubMed
    1. a) Masquida B, Beckert B, Jossinet F, N. Biotechnol. 2010, 27, 170–183; - PubMed
    2. b) Milligan JF, Uhlenbeck OC, Methods Enzymol. 1989, 180, 51–62; - PubMed
    3. c) Milligan JF, Groebe DR, Witherell GW, Uhlenbeck OC, Nucleic Acids Res. 1987, 15, 8783–8798. - PMC - PubMed
    1. a) Lee GH, Lim HK, Jung W, Hah SS, Bull. Korean Chem. Soc 2012, 33, 3861–3863;
    2. b) Skipsey M, Hack G, Hoope TA, Shankey MC, Conway LP, Schroder M, Hodgson DRW, Nucleos. Nucleot. Nucl 2013, 32, 670–681; - PMC - PubMed
    3. c) Zhang L, Sun L, Cui Z, Gottlieb RL, Zhang B, Bioconjug. Chem. 2001, 12, 939–948; - PubMed
    4. d) Williamson D, Cann MJ, Hodgson DRW, Chem Commun. 2007, 47, 5096–5098. - PubMed
    1. a) Shin D, Sinkeldam RW, Tor Y, J. Am. Chem. Soc 2011, 133, 14912–14915; - PMC - PubMed
    2. b) Li Y, Fin A, McCoy L, Tor Y, Angew. Chem. Int. Ed 2017, 56, 1303–1307. - PMC - PubMed

Publication types

MeSH terms

LinkOut - more resources